Cover Image

Subgroups in the treatment of nasal polyposis with dupilumab: a retrospective study

Dupilumab has been shown to be safe and effective in treating chronic rhinosinusitis with polyposis (CRSwNP). There is to this date no published data whether subgroups like patients with aspirin exacerbated respiratory disease (AERD), increased histologic eosinophilia or elevated blood eosinophil or...

Full description

Saved in:
Bibliographic Details
Main Authors: Bertlich, Mattis Ralf Otfried (Author) , Freytag, Saskia (Author) , Dombrowski, Tobias (Author) , Jurmeister, Philipp (Author) , Spiegel, Jennifer Lee (Author) , Bertlich, Ines (Author) , Ihler, Friedrich (Author) , Weiss, Bernhard G. (Author) , Haubner, Frank (Author) , Gröger, Moritz (Author)
Format: Article (Journal)
Language:English
Published: November 11, 2022
In: Medicine
Year: 2022, Volume: 101, Issue: 45, Pages: 1-7
ISSN:1536-5964
DOI:10.1097/MD.0000000000031031
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1097/MD.0000000000031031
Verlag, kostenfrei, Volltext: https://journals.lww.com/md-journal/Fulltext/2022/11110/Subgroups_in_the_treatment_of_nasal_polyposis_with.87.aspx
Get full text
Author Notes:Mattis Bertlich,MD, BSc, Saskia Freytag,PhD, Tobias Dombrowski,MD, Philipp Jurmeister,MD, Jennifer Lee Spiegel,MD, Ines Bertlich,MD, Friedrich Ihler,MD, Bernhard G. Weiss,MD, Frank Haubner,MD, Moritz Gröger, MD
Description
Summary:Dupilumab has been shown to be safe and effective in treating chronic rhinosinusitis with polyposis (CRSwNP). There is to this date no published data whether subgroups like patients with aspirin exacerbated respiratory disease (AERD), increased histologic eosinophilia or elevated blood eosinophil or IgE-levels benefit greater from dupilumab therapy. Moreover, there is no data comparing the efficacy of functional endoscopic sinus surgery (FESS) with dupilumab therapy. We conducted a retrospective chart review of all patients that were treated at a tertiary referral center for CRswNP with dupilumab. We also contacted the patients with a questionnaire to evaluate the efficacy of previous surgeries and dupilumab therapy by visual analogue scale (VAS) and the glasgow benefit inventory (GBI) as well as report on side effects. ...
Item Description:Gesehen am 08.11.2023
Physical Description:Online Resource
ISSN:1536-5964
DOI:10.1097/MD.0000000000031031

Similar Items